NordMedica A/S has been acquired by Eurocept B.V.
The Dutch pharmaceutical company Eurocept B.V. has acquired 100% of the share capital in the Danish specialty pharmaceutical company NordMedica A/S for an undisclosed consideration.
NordMedica A/S was founded in 2003 as a privately held specialty pharmaceutical company focused on the commercialization and marketing of niche pharmaceutical products. The company holds the rights to an oncology product under the brand names Amekrin®, Amsidine® and Amsidyl® in more than 25 countries. The product is based on a chemotherapy drug for the treatment of Acute Myeloid Leukemia (AML) and Acute Lymphatic Leukemia (ALL). All other assets and liabilities together with all employees were transferred to NordMedica International before the transaction.
Eurocept is a rapidly growing company active in the pharmaceutical and homecare market in the Benelux countries. Eurocept offers products and services that answer to pharmaceutical, technological and nursing needs in medical care as well as a unique combination of medical technology and distribution in the therapeutic areas of anesthesia, oncology, pediatrics, psychiatry, immunology, ADHD and urology.
Oaklins' team in Denmark acted as financial and strategic advisor to the seller in this transaction.


Talk to the deal team

Related deals
Presmed Australia has been acquired by ICG
Advanced Health Limited has sold Presmed Australia Pty Ltd (PMA) to ICG.
Learn morePia Mater, a social services firm, has been acquired by SAT Heath
The founders of Pia Mater Ltd. have sold the company to SAT Health.
Learn moreDIAGOMICS has been acquired by ZytoMax, supported by healthcare specialist Archimed investment firm
The owner of DIAGOMICS has sold the company to ZytoMax GmbH.
Learn more